MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and ...

Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...

Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc.

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health ...

The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than ...

Merck MRK is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for fourth-quarter sales and earnings is pegged at $16.19 billion ...

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a ...

Merck & Co., Inc. (NYSE:MRK) is included among the Billionaire Ken Fisher’s Top 11 Dividend Stock Picks. Reuters reported on ...

Merck's biggest growth drivers are cancer drug Keytruda and its HPV vaccine franchise, Gardasil and Gardasil 9. However, both are facing issues. Keytruda will experience a patent cliff by 2028, ...